HalioDx

Veracyte helps doctors make better cancer and disease diagnoses with immuno-oncology diagnostic technologies, including Immunoscore®.

General Information
Company Name
HalioDx
Founded Year
2014
Location (Offices)
France +1
Founders / Decision Makers
Number of Employees
51-200
Industries
Health Care, Pharmaceutical
Funding Stage
Series B
Social Media

HalioDx - Company Profile

HalioDx is a diagnostics company, previously known as Veracyte, with a focus on immuno-oncology diagnostic technologies. Since its founding in 2014, this France-based company has been dedicated to improving patient care by providing crucial answers to clinical questions. Their portfolio of immune scoring solutions, including the Immunoscore® assay, has been developed from Dr. Jérôme Galon's groundbreaking research and is a CLIA or CE-marked test for colon cancer. The company's latest €18.50M Series B investment, secured on 17 January 2018, came from a group of investors including BNP Paribas Developpement, Quest for Growth, Sofipaca, PSIM fund, Sham, and MI Care.

Through their immuno-oncology diagnostic technologies and services, HalioDx aims to contribute to precision medicine and improve treatment decisions, particularly in the current era of immuno-oncology and combination therapies. The company's Immunoscore® assay, which analyzes a tumor's immunological contexture, not only aids in daily decision-making for oncologists in cases of colon cancer but also holds potential applications in diagnosing other cancers. Overall, HalioDx plays a significant role in helping doctors make better cancer and disease diagnoses, ultimately benefitting patient care and outcomes in the health care and pharmaceutical industries.

Taxonomy: Immunooncology, Diagnostics, Precision Medicine, Biomarker Signatures, Oncology Diagnostic Technologies, Immune Scoring, Cancer Diagnoses, Clinical Decision Support, Biopharma Solutions

Funding Rounds & Investors of HalioDx (2)

View All
Funding Stage Amount No. Investors Investors Date
Series B €18.50M 6 PSIM fund, Sham +1 17 Jan 2018
Series A €8.00M 1 01 Mar 2015

Latest News of HalioDx

View All

No recent news or press coverage available for HalioDx.

Similar Companies to HalioDx

View All
INmune Bio Inc. - Similar company to HalioDx
INmune Bio Inc. INmune Bio is focused on modulating components of the innate immune system to activate an immune response to diseases.
Alpha Cancer Technologies Inc. - Similar company to HalioDx
Alpha Cancer Technologies Inc. HARNESSING NATURE TO BEAT CANCER
Normunity - Similar company to HalioDx
Normunity Biotech company creating a new class of precision immuno-oncology medicines that enable normal immunity against cancer.
NEOGAP Therapeutics AB - Similar company to HalioDx
NEOGAP Therapeutics AB Science for cure.
Aomics GmbH - Similar company to HalioDx
Aomics GmbH Aomics is a global clinical data science CRO specialising in delivering end-to-end clinical biometrics solutions to SMEs